Sunitinib dose-escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib clinical efficacy, eventually patients develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Adelaiye, Remi, Ciamporcero, Eric, Miles, Kiersten Marie, Sotomayor, Paula, Bard, Jonathan, Tsompana, Maria, Conroy, Dylan, Shen, Li, Ramakrishnan, Swathi, Ku, Sheng-Yu, Orillion, Ashley, Prey, Joshua, Fetterly, Gerald, Buck, Michael, Chintala, Sreenivasulu, Bjarnason, Georg A., Pili, Roberto
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326587/
https://ncbi.nlm.nih.gov/pubmed/25519701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0208
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados